Boai NKY Medical Holdings Ltd
SZSE:300109

Watchlist Manager
Boai NKY Medical Holdings Ltd Logo
Boai NKY Medical Holdings Ltd
SZSE:300109
Watchlist
Price: 16.81 CNY -2.72%
Market Cap: 8.1B CNY
Have any thoughts about
Boai NKY Medical Holdings Ltd?
Write Note

Boai NKY Medical Holdings Ltd
Cash Paid for Dividends

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Boai NKY Medical Holdings Ltd
Cash Paid for Dividends Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Paid for Dividends CAGR 3Y CAGR 5Y CAGR 10Y
Boai NKY Medical Holdings Ltd
SZSE:300109
Cash Paid for Dividends
-ÂĄ327.7m
CAGR 3-Years
-80%
CAGR 5-Years
-40%
CAGR 10-Years
-48%
Zhejiang Juhua Co Ltd
SSE:600160
Cash Paid for Dividends
-ÂĄ441.4m
CAGR 3-Years
-8%
CAGR 5-Years
0%
CAGR 10-Years
-1%
Hengli Petrochemical Co Ltd
SSE:600346
Cash Paid for Dividends
-ÂĄ9.9B
CAGR 3-Years
0%
CAGR 5-Years
-14%
CAGR 10-Years
-61%
Satellite Chemical Co Ltd
SZSE:002648
Cash Paid for Dividends
-ÂĄ1.8B
CAGR 3-Years
-22%
CAGR 5-Years
-46%
CAGR 10-Years
-21%
Jiangsu Eastern Shenghong Co Ltd
SZSE:000301
Cash Paid for Dividends
-ÂĄ5.6B
CAGR 3-Years
-20%
CAGR 5-Years
-48%
CAGR 10-Years
-51%
Rongsheng Petrochemical Co Ltd
SZSE:002493
Cash Paid for Dividends
-ÂĄ9B
CAGR 3-Years
-33%
CAGR 5-Years
-16%
CAGR 10-Years
-27%
No Stocks Found

Boai NKY Medical Holdings Ltd
Glance View

Market Cap
8.2B CNY
Industry
Chemicals

Boai NKY Medical Holdings Ltd., founded in the heartland of innovation in Henan Province, China, traces its roots back to an era when the world was rapidly advancing in medical technologies yet still bustling with unmet needs for specialized medical supplies. The company pioneered its focus on producing medical polymer materials and channeled its expertise into the creation of polyvinyl pyrrolidone (PVP), a versatile substance used in pharmaceuticals, cosmetics, and various medical applications. This single compound laid the foundation for the firm's ascent, offering it the placement in the global market where its robust application spans from being a pharmaceutical binder to a blood plasma substitute. The magic of Boai NKY lies in its ability to marry scientific research with commercial execution, ensuring its products meet stringent international standards, thereby opening doors to markets in over 50 countries. The company generates revenue by leveraging its strong manufacturing capabilities and R&D investments. This ensures a steady stream of innovative products catering to the global health industry. Boai NKY's business model diversifies risk by spreading its expertise across biomedicine, cosmetics, agriculture, and food sectors, creating a symbiotic revenue framework. By maintaining a diverse product portfolio and nurturing strategic partnerships, the company builds resilience against market volatility and economic downturns. Its revenue is bolstered not only by domestic sales but by a prominent international presence supported by a network of subsidiaries and distributors. This global footprint ensures a stable cash flow, while continuous investment in technology and quality assurance sustains Boai NKY at the forefront of the competitive chemical manufacturing landscape.

Intrinsic Value
12.88 CNY
Overvaluation 23%
Intrinsic Value
Price

See Also

What is Boai NKY Medical Holdings Ltd's Cash Paid for Dividends?
Cash Paid for Dividends
-327.7m CNY

Based on the financial report for Sep 30, 2024, Boai NKY Medical Holdings Ltd's Cash Paid for Dividends amounts to -327.7m CNY.

What is Boai NKY Medical Holdings Ltd's Cash Paid for Dividends growth rate?
Cash Paid for Dividends CAGR 10Y
-48%

Over the last year, the Cash Paid for Dividends growth was -99%. The average annual Cash Paid for Dividends growth rates for Boai NKY Medical Holdings Ltd have been -80% over the past three years , -40% over the past five years , and -48% over the past ten years .

Back to Top